-+ 0.00%
-+ 0.00%
-+ 0.00%

Novartis Announces Remibrutinib Lowers Annualized Relapse Rate By 35.2%, 31.2% In Phase III REMODEL-1, REMODEL-2 Studies To Treat Relapsing Multiple Sclerosis

Benzinga·10/23/2026 16:44:46
Listen to the news

https://www.novartis.com/news/media-releases/novartis-remibrutinib-delivered-comprehensive-disease-control-phase-iii-rms-trials-proven-robust-safety-profile